Free press releases distribution network?

Agency / Source: ChromaDex, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

ChromaDex’ pTeroPure® Achieves GRAS Status - pTeroPure shows promise in heart health, cognitive function and healthy aging (OTCBB: CDXC)
ChromaDex’ pTeroPure® Achieves GRAS Status


PRZOOM - /newswire/ - Irvine, CA, United States, 2011/06/07 - pTeroPure shows promise in heart health, cognitive function and healthy aging (OTCBB: CDXC).

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


ChromaDex Corporation today announced that an independent scientific panel of experts supports the GRAS (generally recognized as safe) status of its ingredient pTeroPure®. pTeroPure is an ultra-pure formulation of the naturally occurring compound pterostilbene, found in blueberries. pTeroPure has the potential to impact heart health by supporting cholesterol and blood pressure while providing additional benefits related to cognitive function and healthy aging. By achieving GRAS status, ChromaDex can now expand pTeroPure into the food and beverage industry, moving beyond the supplement industry where it has recently been incorporated in more than 20 nutraceutical products.

Following a comprehensive review of the safety, toxicology and proposed usage, an independent panel of experts reached a unanimous decision that pTeroPure is safe for use in food and beverage products. GRAS is a U.S. Food and Drug Administration (FDA) designation that an ingredient in food is considered safe by experts. The Allowable Daily Intake (ADI) for pTeroPure is up to 30mg/kg (or 1.89 grams) per day for food use and intake.

“The industry experts from the American Institute for Biosocial and Medical Research, including former U.S. Department of Agriculture and FDA staffers, all agreed that pTeroPure merits this designation,” remarked Frank Jaksch, CEO of ChromaDex, Inc. “Their acceptance of GRAS for pTeroPure is a testament to the extensive scientific research for pterostilbene in general and the exceptional technical information that demonstrates the safety of pTeroPure in particular.”

The first human clinical trial to evaluate pTeroPure is currently underway at the University of Mississippi to evaluate the compound in patients with lipid (cholesterol) disorders. The primary outcome includes standard lipid laboratory markers (HDL, LDL and triglycerides), and secondary endpoints include blood pressure, markers of oxidative stress, and safety. ChromaDex holds exclusive worldwide patent rights for pterostilbene based on technology licensed from the University of Mississippi and the USDA.

William Spengler, President, ChromaDex, Inc. states,“Achieving GRAS status for pTeroPure provides a significant new commercial opportunity for the Company to enter the multi-billion dollar market segment for natural food and beverage ingredients. Based on a scientific foundation, we are seeking to establish a leadership role for pTeroPure in the rapidly growing market for health and wellness.”

pTeroPure was recently named the 2010 North American Most Promising Ingredient of the Year by the prestigious independent research company, Frost & Sullivan. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the skincare and pharmaceutical markets. For more information about pTeroPure, visit or call 949-600-9694.

About ChromaDex
ChromaDex ( is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an impressive pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights.

ChromaDex Forward-Looking Statements
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Investor Inquiries:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
P: 415-389-4670 / E: John[.]

pTeroPure Contact
Jeremy Bartos, Product Development Manager
P: 949-600-9694 / E: jeremyb[.]

ChromaDex Contact
Laura Carney, Administrative Assistant
P: 949-419-0288 / E: laurac[.]

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Agency / Source: ChromaDex, Inc.


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

ChromaDex’ pTeroPure® Achieves GRAS Status

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Contact: Carolyn Hawley - 
619-849-5375 carolyn[.]
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any ChromaDex, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Press Releases From ChromaDex, Inc. / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy
Greenphire Continues Commitment to Clinical Research Site Sustainability and Innovation at Global Site Solutions Summit
Frost & Sullivan Highlights argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPL
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...


Visit  MagLar, Inc.

Visit  NAKIVO, Inc.


  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today